Open-label, single-arm, Phase IIIb study to demonstrate the efficacy and safety of a single dose of the new L-praziquantel orally disintegrating tablets in children age 2 to 6 years infected with Schistosoma haematobium (urogenital schistosomiasis)
100 Clinical Results associated with Merck Pty Ltd. (Australia)
0 Patents (Medical) associated with Merck Pty Ltd. (Australia)
100 Deals associated with Merck Pty Ltd. (Australia)
100 Translational Medicine associated with Merck Pty Ltd. (Australia)